By Abigail Townsend
Date: Wednesday 20 Oct 2021
(Sharecast News) - Biogen raised its full-year earnings guidance on Wednesday, despite weak sales of breakthrough Alzheimer's drug Aduhelm.
Currency | US Dollars |
Share Price | $ 118.61 |
Change Today | $ 3.32 |
% Change | 2.88 % |
52 Week High | $236.72 |
52 Week Low | $114.66 |
Volume | 1,206,338 |
Shares Issued | 145.80m |
Market Cap | $17,293m |
RiskGrade | 259 |
Strong Buy | 6 |
Buy | 9 |
Neutral | 20 |
Sell | 0 |
Strong Sell | 0 |
Total | 35 |
Time | Volume / Share Price |
16:00 | 282,285 @ $118.61 |
15:59 | 176 @ $118.60 |
15:59 | 100 @ $118.61 |
15:59 | 100 @ $118.60 |
15:59 | 100 @ $118.60 |
You are here: research